TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF EUROPE RICE PROTEIN BASED INFANT FORMULA MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 EUROPE RICE PROTEIN BASED INFANT FORMULA MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 DBMR VENDOR SHARE ANALYSIS
2.9 MULTIVARIATE MODELING
2.10 PRODUCTS LIFELINE CURVE
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 RISING POPULATION OF WORKING MOTHERS
3.1.2 GROWING INFANT POPULATION
3.1.3 INCREASING CASES OF BREAST CANCER
3.1.4 RICE PROTEIN BASED INFANT FORMULA IS WIDELY ACCEPTED AS NON-ALLERGIC PRODUCT
3.2 RESTRAINT
3.2.1 STRINGENT REGULATION
3.3 OPPORTUNITIES
3.3.1 GROWING ECONOMIES AND DISPOSABLE INCOME IN EMERGING REGIONS
3.3.2 INCREASING AWARENESS REGARDING IMPORTANCE OF NUTRITION FOR INFANTS
3.4 CHALLENGES
3.4.1 HIGH CONTENT OF TOXIC CHEMICALS IN RICE PROTEIN BASED INFANT FORMULA
3.4.2 IMPROPER PACKAGING OF BABY FOOD
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 EUROPE RICE PROTEIN BASED INFANT FORMULA MARKET, BY PRODUCT TYPE
6.1 OVERVIEW
6.2 FOLLOW-ON FORMULA
6.3 TODDLER FORMULA
6.4 STANDARD FORMULA
6.5 SPECIAL FORMULA
7 EUROPE RICE PROTEIN BASED INFANT FORMULA MARKET, BY TYPE
7.1 OVERVIEW
7.2 UNFORMULATED
7.3 FORMULATED
7.3.1 VEGETABLES
7.3.2 FRUITS
7.3.3 CEREAL
8 EUROPE RICE PROTEIN BASED INFANT FORMULA MARKET, BY FORM
8.1 OVERVIEW
8.2 NON-GMO
8.3 GMO
9 EUROPE RICE PROTEIN BASED INFANT FORMULA MARKET, BY INFANT AGE
9.1 OVERVIEW
9.2 6-12 MONTHS
9.3 1-3 YEARS
9.4 0-6 MONTHS
10 EUROPE RICE PROTEIN BASED INFANT FORMULA MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 STORE-BASED RETAILER
10.2.1 CONVENIENCE STORES
10.2.2 SUPERMARKETS/HYPERMARKETS
10.2.3 SPECIALTY STORES
10.2.4 GROCERY STORES
10.2.5 WHOLESALERS
10.3 NON-STORE RETAILER
10.3.1 ONLINE
10.3.2 VENDING
11 EUROPE RICE PROTEIN BASED INFANT FORMULA MARKET, BY GEOGRAPHY
11.1 EUROPE
11.1.1 GERMANY
11.1.2 FRANCE
11.1.3 U.K.
11.1.4 ITALY
11.1.5 SPAIN
11.1.6 NETHERLANDS
11.1.7 POLAND
11.1.8 SWEDEN
11.1.9 SWITZERLAND
11.1.10 BELGIUM
11.1.11 DENMARK
11.1.12 RUSSIA
11.1.13 TURKEY
11.1.14 REST OF EUROPE
12 EUROPE RICE PROTEIN BASED INFANT FORMULA MARKET, COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: EUROPE
12.2 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
13 COMPANY PROFILE
13.1 LACTALIS INTERNATIONAL
13.1.1 COMPANY SNAPSHOT
13.1.2 COMPANY SHARE ANALYSIS
13.1.3 PRODUCT PORTFOLIO
13.1.4 RECENT DEVELOPMENTS
13.2 NOVALAC
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENT
13.3 BAYER AG
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENT
13.4 LABORATORIOS ORDESA
13.4.1 COMPANY SNAPSHOT
13.4.2 COMPANY SHARE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENT
13.5 BIOLAB PHARMA
13.5.1 COMPANY SNAPSHOT
13.5.2 PRODUCT PORTFOLIO
13.5.3 RECENT DEVELOPMENT
13.6 KATE FARMS
13.6.1 COMPANY SNAPSHOT
13.6.2 PRODUCT PORTFOLIO
13.6.3 RECENT DEVELOPMENT
13.7 LA MANDORLE
13.7.1 COMPANY SNAPSHOT
13.7.2 PRODUCT PORTFOLIO
13.7.3 RECENT DEVELOPMENT
13.8 NUCITEC SA DE CV
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENT
14 QUESTIONNAIRE
15 CONCLUSION
16 RELATED REPORTS